# Venus Remedies Ltd (VENUSREM)
> Exchange: NSE | Sector: Pharma | ISIN: INE411B01019

## Price
Current Price: ₹1030.55
Day Change: -1.15%
52W High: ₹1119
52W Low: ₹331.5
Market Cap: ₹1,220 Cr

## Valuation
P/E: 16
P/B: 2.05
EPS: ₹57.07
Book Value: ₹444.62
Dividend Yield: 0%

## Returns
1Y Return: 80.55%

## Profitability
ROE: 0%
ROCE: 23.74%
Debt/Equity: 0.02
Revenue Growth: 1.9%
Profit Growth: 36.1%
EBITDA Margin: 15.7%
Operating Margin: 17.18%

## About
Venus Remedies Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Venus Remedies Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Corporate Action-Board to consider Dividend
- Announcement: Board Meeting Intimation for Board Meeting Scheduled For 26Th May 2026.
- BSE Filing: Corporate Action-Board to consider Dividend

## Access
Current tier: anonymous
More history: Register free to see 9 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:05.656Z
Price History Updated: 2026-05-18T22:59:05.182Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:59:05.182Z
Quant Updated: 2026-05-18T22:59:05.182Z
Sentiment Updated: 2026-05-18T22:59:05.182Z
Financials Status: current
Financials Updated: 2026-05-18T18:32:14.885Z
Financials Last Attempt: 2026-05-18T18:32:14.885Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2015)
Revenue: ₹531 Cr
Operating Profit: ₹138 Cr (OPM 26%)
Net Profit: ₹64 Cr
Tax: ₹69 Cr

## Annual P&L History
Mar 2015: Rev ₹531Cr | PAT ₹64Cr | OPM 26%
Mar 2016: Rev ₹455Cr | PAT ₹5Cr | OPM 20%
Mar 2017: Rev ₹407Cr | PAT ₹2Cr | OPM 20%

## Balance Sheet (Mar 2015)
Total Assets: ₹834 Cr
Total Liabilities: ₹834 Cr
Borrowings: ₹289 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Pawan  Chaudhary, Chairman, MD & CFO
- Ashutosh  Jain B.A., LL.B, CEO, Head of Legal, Regulatory Dept. & Whole-Time Director
- Manu  Chaudhary, Joint MD, Head of Research, Development & Operations and Whole-Time Director
- Akshansh  Chaudhary, CTO & Executive Time Director
- Peeyush  Jain, Deputy MD, Head of Indian Marketing Operations & Whole-Time Director

---
Source: rupiya.io/stocks/venusrem
Disclaimer: For research and education only. Not investment advice.